Contrasting Actuate Therapeutics (NASDAQ:ACTU) and Bavarian Nordic (OTCMKTS:BVNRY)

Actuate Therapeutics (NASDAQ:ACTU) and Bavarian Nordic (OTCMKTS:BVNRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Actuate Therapeutics and Bavarian Nordic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Bavarian Nordic	19.74%	9.37%	8.10%

Analyst Ratings

This is a summary of recent ratings and price targets for Actuate Therapeutics and Bavarian Nordic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1	0	2	0	2.33
Bavarian Nordic	0	0	0	0	0.00

Actuate Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 779.40%. Given Actuate Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Actuate Therapeutics is more favorable than Bavarian Nordic.

Valuation & Earnings

This table compares Actuate Therapeutics and Bavarian Nordic”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23 million	($0.97)	-2.05
Bavarian Nordic	$945.43 million	2.40	$208.23 million	$0.76	12.53

Bavarian Nordic has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Actuate Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Bavarian Nordic has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Summary

Bavarian Nordic beats Actuate Therapeutics on 8 of the 11 factors compared between the two stocks.

About Actuate Therapeutics

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.